ArQule, Inc. (NASDAQ:ARQL) went up to recover about 348.88% since recording its record low price of $2.23. The stock experienced -4.58% slump, arriving at $10.01 on 6/24/2019. During the day, the stock price traveled from $9.96 to $10.68. This company shares are -5.69% up from its target price of $9.44 and the current market capitalization stands at $1.08B. The recent change has given its price a 45.09% lead over SMA 50 and -4.76% deficit over its 52-week high. The stock witnessed 36.38% gains, 101.81% gains and 297.22% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ARQL’s volatility during a week at 6.98% and during a month it has been found around 8.54%.
What Does ArQule, Inc. (ARQL) Do?
The company describes itself in regulatory filings as, “ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products. The company was founded in 1993 and is headquartered in Burlington, MA.” [Text can be found here: https://www.marketwatch.com/investing/stock/ARQL/profile under company description.]ArQule, Inc. (ARQL) Top Holders
Institutional investors currently hold around $828 million or 80.6% in ARQL stock. Look at its top three institutional owners: First Eagle Investment Management, Llc owns $168.69 million in ArQule, Inc., which represents roughly 15.62% of the company’s market cap and approximately 20.37% of the institutional ownership. Similar statistics are true for the second largest owner, Nantahala Capital Management, Llc, which owns 12,005,361 shares of the stock are valued at $125.94 million. The third largest holder is Blackrock Inc., which currently holds $89.15 million worth of this stock and that ownership represents nearly 8.25% of its market capitalization.
At the end of March reporting period, 61 institutional holders increased their position in ArQule, Inc. (NASDAQ:ARQL) by some 5,235,255 shares, 51 decreased positions by 5,988,621 and 29 held positions by 67,705,727. That puts total institutional holdings at 78,929,603 shares, according to SEC filings. The stock grabbed 25 new institutional investments totaling 1,326,795 shares while 14 institutional investors sold out their entire positions totaling 775,628 shares.ArQule, Inc. (NASDAQ:ARQL) Insider Trades
Multiple company employees have indulged in significant insider trading. ArQule, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Nussbaum Ran has acquired 181,818 shares of ArQule, Inc. (ARQL) in the trading session dated Jul. 13, 2018. These shares are worth $999,999 and were traded at $5.5 each. The SEC filing shows that BIOTECHNOLOGY VALUE FUND L P performed a sale of 1,035,939 shares. The disposed these shares by way of transaction on May. 30, 2018. The company’s shares were given away at $5 per share worth to an income of some $5,179,695 to the account of BIOTECHNOLOGY VALUE FUND L P.
CEO, Pucci Paolo, purchased 15,000 common shares of ArQule, Inc. (ARQL) in the open market. In a transaction dated May. 18, 2018, the shares were bought at an average price of $3.39, giving away a sum of $50,850. After this purchase, 420,494 common shares of ARQL are directly owned by the insider, with total stake valued at $4,209,145.
In the transaction dated May. 18, 2018, a great number of shares acquired came courtesy the Director; Nussbaum Ran added a total of 8,611 shares at an average price of $3.29, amounting to approximately $28,330. The insider now directly owns 8,611 shares worth $86,196.ArQule, Inc. (ARQL) Analyst Guide
Several analysts have released their opinion on ArQule, Inc. (NASDAQ:ARQL), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation [T1].